30 August 2022 – 07:36
Protect children aged 5 to 11 against corona? UMC Utrecht is investigating whether one shot of the Pfizer-BioNTech vaccine protects as well as two shots in children who have had corona. Children who wish to be vaccinated can enroll in this study. Elsa, seven, is the first child to recently participate in this CoVacc study.
Elsa, a fictitious name for privacy, is a seven-year-old girl who herself wanted to participate in the study. So her mother gave her up. “She wanted to participate, is fascinated by hospital series and is always eager to help other children. It’s an already approved vaccine, so I didn’t see any problems.’
Why this research in children at this young age? Dr. Patricia Bruijning, paediatrician, epidemiologist and principal researcher of the CoVacc study: “When children are vaccinated against corona, they get two injections as standard. But if you’ve had corona before, sometimes you only get one shot. We want to investigate – for children , who want to be vaccinated – whether one shot works as well as two. But with possibly fewer side effects and less stress.”
The CoVacc study is looking for 200 children aged 5 to 11 in Europe, including the Netherlands, to investigate what is actually best: one or two injections.
Children who are at least 5 and at most 11 years old can participate in the CoVacc study. Parents or guardians can register them. It is possible to participate if the child has already had corona and has not yet received a vaccination against corona, but would like to.
You can register for this study via https://www.vaccinitiestudie.nl/onderzoeken/covacc. By registering, no obligation is entered into.
Approved corona vaccine
The study uses the pediatric vaccine from Pfizer-BioNTech, which is approved by the EMA (European Medicine Agency). Bruijning: “The standard vaccination schedule for children aged 5 and over prescribes that two injections of 10 micrograms are given. In some countries, however, only 1 shot is given if children have had corona before and you do not belong to a risk group. An injection causes half the stress for the child and the parents and is expected to cause fewer side effects, but does it work just as well? To investigate this, half of the children receive one injection, and the other half two injections. In addition, we want to know how long one or two injections provide protection for young children and whether it provides protection against new variants of SARS-CoV-2.”
CoVacc is part of the European VACCELERATE project “A Pan-European Vaccine Development Network”, which creates a network ready to tackle new pandemics and increase vaccine development capacity in Europe. VACCELERATE has received support from the European Union’s Horizon 2020 Research and Innovation Program under grant agreement no. 101037867.